8-K: Aligos Reports Q3 2025 Results, Pevifoscorvir Progress

Aligos Therapeutics announced third quarter 2025 financial results and pipeline updates, highlighting progress in its Phase 2 HBV study and promising preclinical data for ALG-055009.

Summary

• The Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic HBV infection is enrolling well, with subjects dosed across the U.S., China, Hong Kong, and Canada.
• Interim data for the pevifoscorvir sodium Phase 2 study are projected in 1H and 2H 2026, with topline data anticipated in 2027.
• Data from the Phase 1 pevifoscorvir sodium study, including post-treatment data, will be presented at The Liver Meeting 2025 in November 2025.
• Preclinical data for ALG-055009 (a THRagonist for obesity and MASH) demonstrated profound synergistic effects in body weight loss when combined with semaglutide or tirzepatide in a diet-induced obese mouse model, also showing enhanced antihyperlipidemic effects.
• Evaluation of funding options for ALG-055009, including potential out-licensing, is ongoing.
• Cash, cash equivalents, and investments totaled $99.1 million as of September 30, 2025, an increase from $56.9 million as of December 31, 2024.
• The current cash position is expected to provide sufficient funding for planned operations into the third quarter of 2026.
• Net loss for the third quarter of 2025 was $31.5 million, or $(3.04) per common share, compared to a net loss of $19.3 million, or $(3.07) per common share, for the same period in 2024.
• Research and development (R&D) expenses increased to $23.9 million in Q3 2025 from $16.8 million in Q3 2024, primarily due to the pevifoscorvir sodium Phase 2a clinical trial.
• General and administrative (G&A) expenses increased to $5.2 million in Q3 2025 from $4.6 million in Q3 2024, primarily due to an increase in legal and other related expenses.
• The loss from the change in fair value of 2023 common warrants was $4.2 million in Q3 2025, compared with a loss of $0.1 million for the same period of 2024.

Sentiment

Score: 5

Explanation: Mixed sentiment. Positive clinical and preclinical progress is offset by a significant increase in net loss and operating expenses, alongside a substantial loss from warrant fair value changes. The cash runway is stable but finite, indicating future funding needs.

Positives

• The Phase 2 B-SUPREME study for pevifoscorvir sodium is enrolling well, with subjects dosed across multiple countries, indicating good operational progress.
• Preclinical data for ALG-055009 showed profound synergistic effects in body weight loss and enhanced antihyperlipidemic effects when combined with incretin receptor agonists (semaglutide or tirzepatide) in a diet-induced obese mouse model, suggesting strong therapeutic potential.
• Cash, cash equivalents, and investments increased to $99.1 million as of September 30, 2025, from $56.9 million as of December 31, 2024, strengthening the company's financial liquidity.
• The company's cash runway is extended into the third quarter of 2026, providing operational stability for the near term.
• Eight abstracts, including one oral presentation on pevifoscorvir sodium Phase 1 monotherapy, were accepted for presentation at The Liver Meeting 2025, indicating scientific recognition and progress.

Negatives

• Net loss significantly increased to $31.5 million in Q3 2025 from $19.3 million in Q3 2024, indicating a higher burn rate.
• Research and development (R&D) expenses increased by $7.1 million to $23.9 million in Q3 2025, primarily due to the pevifoscorvir sodium Phase 2a clinical trial, contributing to the increased net loss.
• General and administrative (G&A) expenses increased to $5.2 million in Q3 2025, primarily due to higher legal and other related expenses.
• The loss from the change in fair value of 2023 common warrants increased substantially to $4.2 million in Q3 2025 from $0.1 million in Q3 2024, impacting the bottom line.
• Revenue from collaborations and customers decreased for both the three and nine months ended September 30, 2025, compared to the same periods in 2024.

Risks

• Risks and uncertainties inherent in the drug development process, including Aligos' clinical-stage of development.
• Risks associated with designing and conducting clinical trials.
• Regulatory approval processes and the timing of regulatory filings.
• Challenges associated with manufacturing drug products.
• Ability to successfully establish, protect, and defend intellectual property.
• Matters that could affect the sufficiency of Aligos' capital resources to fund operations.
• Reliance on third parties for manufacturing and development efforts.
• Changes in the competitive landscape.
• Impact of global events and other macroeconomic conditions on Aligos' business.

Future Outlook

Aligos Therapeutics expects interim data from its Phase 2 B-SUPREME study of pevifoscorvir sodium in 1H and 2H 2026, with topline data anticipated in 2027. The company also anticipates presenting preclinical data for ALG-055009 at a future scientific conference and is evaluating options, including out-licensing, to fund its continued development. The current cash, cash equivalents, and investments are projected to provide sufficient funding for planned operations into the third quarter of 2026.

Management Comments

• "Our Phase 2 B-SUPREME study of pevifoscorvir sodium (pevy) is enrolling nicely, with subjects dosed across a number of countries, including the U.S., China, Hong Kong, and Canada." Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer.
• "We are pleased with the progress to date and look forward to interim readouts in 2026." Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer.
• "Importantly, we look forward to sharing additional pevy data next week at AASLD's The Liver Meeting." Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer.
• "We maintain our enthusiasm regarding the potential for pevy as well as our entire development pipeline, including ALG-055009, which is in continued discussions with potential partners for obesity and MASH." Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer.

Industry Context

The company's focus on liver and viral diseases, particularly chronic HBV, aligns with ongoing global health challenges. The development of ALG-055009 as a THRagonist for obesity and MASH, especially in combination with incretin receptor agonists like semaglutide and tirzepatide, positions Aligos within a highly competitive and rapidly evolving metabolic disease landscape. The synergistic effects observed in preclinical models suggest a potential for enhanced efficacy, which is a key differentiator in the crowded obesity and MASH therapeutic areas where combination therapies are gaining prominence.

Comparison to Industry Standards

• ALG-055009's preclinical data showing synergistic effects with semaglutide (Novo Nordisk's Wegovy/Ozempic) and tirzepatide (Eli Lilly's Zepbound/Mounjaro) in a diet-induced obese mouse model suggests a potential competitive advantage in the obesity and MASH markets. These incretin receptor agonists are current market leaders, and Aligos's data indicates its THRagonist could enhance their efficacy, potentially offering a 'best-in-class' combination therapy.
• The B-SUPREME study for pevifoscorvir sodium aims to be a 'first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection.' This positions it against existing HBV treatments like tenofovir disoproxil fumarate (used as an active control in the study) and other investigational compounds in a field with high unmet medical needs for functional cure.

Stakeholder Impact

• Shareholders: Increased net loss and operating expenses could negatively impact profitability and share value. However, positive clinical progress and promising preclinical data for pipeline assets could drive future value. The increased cash position provides stability for the near term.
• Patients: Progress in the pevifoscorvir sodium Phase 2 study and promising preclinical data for ALG-055009 offer potential for improved therapies for chronic HBV, obesity, and MASH.
• Employees: Continued clinical development and pipeline progress suggest ongoing work and potential for growth.
• Potential Partners: The ongoing discussions for out-licensing ALG-055009 indicate potential for new collaborations and revenue streams.

Next Steps

• Present additional pevifoscorvir sodium data at AASLD's The Liver Meeting in November 2025.
• Present preclinical data for ALG-055009 at a future scientific conference.
• Continue evaluation of funding options, including potential out-licensing, for ALG-055009.
• Interim data readouts for pevifoscorvir sodium Phase 2 B-SUPREME study in 1H and 2H 2026.
• Topline data for pevifoscorvir sodium Phase 2 B-SUPREME study anticipated in 2027.

Key Dates

Recommendation

While the company shows promising clinical and preclinical progress with its pipeline assets, particularly the enrollment in the Phase 2 HBV study and synergistic preclinical data for ALG-055009, the significant increase in net loss and operating expenses raises concerns about the burn rate. The cash runway into Q3 2026 provides some stability, but future capital needs are implied. The substantial loss from warrant fair value changes also adds a layer of financial volatility. Given the mixed financial performance against positive operational updates, a 'hold' recommendation is appropriate, awaiting further clinical data and clarity on future funding strategies.

Keywords

Aligos Therapeutics, ALGS, biotechnology, clinical stage, liver diseases, viral diseases, chronic hepatitis B, HBV, pevifoscorvir sodium, CAM-E, Phase 2, B-SUPREME study, ALG-055009, THRagonist, obesity, MASH, metabolic dysfunction-associated steatohepatitis, semaglutide, tirzepatide, preclinical data, financial results, Q3 2025, R&D expenses, G&A expenses, net loss, cash runway, SEC filing, 8-K